Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT01068041
PHASE2

Effects of PH3 in Diabetic Nephropathy

Sponsor: PhytoHealth Corporation

View on ClinicalTrials.gov

Summary

The primary objective of this clinical study is to evaluate the effectiveness and safety of PH3 for patients with diabetic nephropathy. The secondary objectives are to identify the optimal dosage for subsequent studies and to provide basis for the next confirmatory study in study design, endpoints, and study methodologies.

Key Details

Gender

All

Age Range

18 Years - 70 Years

Study Type

INTERVENTIONAL

Enrollment

100

Start Date

2010-08

Completion Date

2015-09

Last Updated

2026-09-18

Healthy Volunteers

No

Interventions

DRUG

PH3

Each PH3 tablet, 530 mg/tablet, contains 250 mg of active ingredient. The placebo tablet contains no active ingredient.

Locations (3)

Taichung Veterans General Hospital

Taichung, Taiwan

Tri-Service General Hospital

Taipei, Taiwan

Taipei Veterans General Hospital

Taipei, Taiwan